For UK MedTech companies
Your clinical evidence is strong. UK payers are still saying no.
NHS commissioners and private insurers fund on health economics, not clinical outcomes alone. Without a UK-specific value case, even well-evidenced medtech stalls at the reimbursement stage indefinitely.
Two minutes. Solva follows up with specific health economics and market access options.
- Delayed or failed market access for innovative MedTech products in the UK
- Products with strong clinical benefits struggling to gain adoption due to lack of economic justification
- Increased internal resource strain as companies attempt to retrospectively generate health economic evidence
- Loss of competitive advantage to companies that effectively demonstrate value to UK payers
- Diversion of R&D resources to address market access hurdles rather than new product development
- Increased workload for commercial and regulatory teams attempting to navigate complex reimbursement pathways
- Significant loss of potential revenue from the NHS and private healthcare markets
- Reduced return on investment for product development and clinical trials
- Damage to company reputation as an innovator if products fail to reach patients
- Reduced attractiveness to investors due to market access challenges
- The primary root cause is the evolving landscape of UK healthcare reimbursement, where payers (NHS commissioners and private insurers) increasingly demand robust health economic evidence (e.g., QALYs, budget impact models) beyond clinical efficacy alone.
- Many MedTech companies, historically focused on clinical data for regulatory approval, lack the specialized expertise or resources to develop UK-specific health economic cases, leading to a disconnect between perceived product value and payer requirements.
- This is compounded by a lack of early engagement with market access strategies during product development.
No verified UK data available
Source: Search conducted on NICE and UK health economics literature (June 2026)
How to fix it
A UK health economics strategy building the QALY-based evidence, the budget impact model, and the NHS business case gives payers the evidence they need to make a positive reimbursement decision.
Frequently asked questions
Why does this problem persist?
UK payers - NHS commissioners and private insurers - make reimbursement decisions based on health economics evidence, not clinical evidence alone. Most MedTech companies don't have a UK-specific health economics case.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.